Literature DB >> 15526364

Effects of phosphorothioate anti-sense oligodeoxynucleotides on colorectal cancer cell growth and telomerase activity.

Xi-Shan Wang1, Kuan Wang, Xue Li, Song-Bin Fu.   

Abstract

AIM: To investigate the inhibitory effect of phosphorothioate anti-sense oligodeoxynucleotides (PASODN) on colorectal cancer LS-174T cells in vitro and the mechanism of inhibition of telomerase activity in these cells.
METHODS: PASODN were used to infect LS-174T cells and block human telomerase RNA (hTR) through anti-sense technology. The inhibitory effect of PASODN was evaluated by colony-forming inhibition assay and growth curve. Changes of telomerase activity in LS-174T cells were detected by polymerase chain reaction-enzyme-linked immunosorbent assay (PCR-ELISA), and the level of apoptosis was analyzed by flow cytometry (FCM) assay.
RESULTS: PASODN showed a dose and time-dependent inhibition of cell proliferation. The optimal dosage of PASODN was 10 mumol/L. The colony-forming efficiency was 10.3% in PASODN group after 10 d, whereas that in phosphorothioate mis-sense oligodeoxynucleotides (PMSODN) group with the same concentration and in PBS group (blank control) was 49.1% and 50.7%, respectively. PCR-ELISA results indicated that telomerase activity in the PASODN group was obviously inhibited in comparison with in the control groups (P<0.01, t = 3.317 and 3.241, t0.01(20) = 2.845). Meanwhile, before the number of cells was decreased, the morphological changes were observed in the cells of PASODN group. The cells in PASODN group showed the apoptotic peak at 72 h after infection, whereas the control group did not show.
CONCLUSION: Specific sequence oligonucleotides can inhibit telomerase activity and lead to cell apoptosis, suggesting a novel treatment strategy for malignant tumors induced by telomerase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526364      PMCID: PMC4576226          DOI: 10.3748/wjg.v10.i23.3455

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  Antisense telomerase RNA induced human gastric cancer cell apoptosis.

Authors:  Fang-Xin Zhang; Xue-Yong Zhang; Dai-Ming Fan; Zi-Yun Deng; Yan Yan; Han-Ping Wu; Jun-Jie Fan
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Telomerase catalytic subunit homologs from fission yeast and human.

Authors:  T M Nakamura; G B Morin; K B Chapman; S L Weinrich; W H Andrews; J Lingner; C B Harley; T R Cech
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

Review 3.  Antisense oligonucleotides: promise and reality.

Authors:  I Lebedeva; C A Stein
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

4.  Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.

Authors:  D J Bearss; M A Subler; J E Hundley; D A Troyer; R A Salinas; J J Windle
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

Review 5.  Potential roles of antisense technology in cancer chemotherapy.

Authors:  S T Crooke
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

6.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

Review 7.  Telomerase inhibition, oligonucleotides, and clinical trials.

Authors:  David R Corey
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

Review 8.  Clinical utility of telomerase in cancer.

Authors:  Eiso Hiyama; Keiko Hiyama
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

9.  Fomivirsen.

Authors:  Lisa R. Grillone; Rene Lanz
Journal:  Drugs Today (Barc)       Date:  2001-04       Impact factor: 2.245

10.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

View more
  1 in total

1.  Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues.

Authors:  Guiyu Wang; Xishan Wang; Shuhuai Wang; Hongtao Song; Haiming Sun; Weiguang Yuan; Bo Cao; Jing Bai; Songbin Fu
Journal:  Int J Colorectal Dis       Date:  2008-03-14       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.